You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Johnson and Johnson
McKesson
Merck
Medtronic

Last Updated: February 23, 2024

CLINICAL TRIALS PROFILE FOR LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Levaquin In Dextrose 5% In Plastic Container

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00035347 ↗ Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia Completed Pfizer Phase 4 2001-01-01 A trial in which patients over 18 years of age who are hospitalized with community acquired pneumonia and are otherwise eligible for entry into the study are randomly selected to receive one of two treatment regimens. After written informed consent is obtained, patients will receive one of the following two treatment regimens: 1) intravenous administration of azithromycin and ceftriaxone followed by azithromycin tablets, or 2) intravenous administration of levofloxacin followed by levofloxacin tablets. At least four study visits are normally conducted up to approximately one month after starting therapy. The objective of this study is to compare the safety and efficacy of the two treatment regimens.
NCT00176306 ↗ Levofloxacin Pharmacokinetics (PK) in the Severely Obese Completed Ortho-McNeil Pharmaceutical Phase 4 2005-01-01 Obesity is known to affect the concentrations of certain medications in the body. Levofloxacin is a commonly used antibiotic. Based on what the investigators know about levofloxacin and how it moves through the body, obesity may affect levofloxacin concentrations. This study aims to show the effect of obesity on levofloxacin concentrations. The hypothesis is as follows: A 750 mg intravenous (IV) dose of levofloxacin administered to severely obese, critically ill patients will yield serum concentrations that are likely to be therapeutic.
NCT00176306 ↗ Levofloxacin Pharmacokinetics (PK) in the Severely Obese Completed Joel Thompson, PhD Phase 4 2005-01-01 Obesity is known to affect the concentrations of certain medications in the body. Levofloxacin is a commonly used antibiotic. Based on what the investigators know about levofloxacin and how it moves through the body, obesity may affect levofloxacin concentrations. This study aims to show the effect of obesity on levofloxacin concentrations. The hypothesis is as follows: A 750 mg intravenous (IV) dose of levofloxacin administered to severely obese, critically ill patients will yield serum concentrations that are likely to be therapeutic.
NCT00176306 ↗ Levofloxacin Pharmacokinetics (PK) in the Severely Obese Completed University of Kentucky Phase 4 2005-01-01 Obesity is known to affect the concentrations of certain medications in the body. Levofloxacin is a commonly used antibiotic. Based on what the investigators know about levofloxacin and how it moves through the body, obesity may affect levofloxacin concentrations. This study aims to show the effect of obesity on levofloxacin concentrations. The hypothesis is as follows: A 750 mg intravenous (IV) dose of levofloxacin administered to severely obese, critically ill patients will yield serum concentrations that are likely to be therapeutic.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Levaquin In Dextrose 5% In Plastic Container

Condition Name

Condition Name for Levaquin In Dextrose 5% In Plastic Container
Intervention Trials
Chronic Sinusitis 1
Sarcoidosis; Antimycobacterial Therapy 1
COPD Exacerbation 1
Neutropenia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Levaquin In Dextrose 5% In Plastic Container
Intervention Trials
Infection 4
Pneumonia 4
Communicable Diseases 4
Tuberculosis 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Levaquin In Dextrose 5% In Plastic Container

Trials by Country

Trials by Country for Levaquin In Dextrose 5% In Plastic Container
Location Trials
United States 127
Canada 13
Georgia 4
Ukraine 3
Latvia 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Levaquin In Dextrose 5% In Plastic Container
Location Trials
Florida 7
California 7
Texas 6
Ohio 6
New York 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Levaquin In Dextrose 5% In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Levaquin In Dextrose 5% In Plastic Container
Clinical Trial Phase Trials
Phase 4 7
Phase 3 6
Phase 2/Phase 3 1
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Levaquin In Dextrose 5% In Plastic Container
Clinical Trial Phase Trials
Completed 14
Terminated 3
Unknown status 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Levaquin In Dextrose 5% In Plastic Container

Sponsor Name

Sponsor Name for Levaquin In Dextrose 5% In Plastic Container
Sponsor Trials
Pfizer 2
Westat 2
Boston University 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Levaquin In Dextrose 5% In Plastic Container
Sponsor Trials
Other 32
Industry 16
NIH 5
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Johnson and Johnson
Harvard Business School
Mallinckrodt
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.